Literature DB >> 10974209

Apparent involvement of the A(2A) subtype adenosine receptor in the anti-inflammatory interactions of CGS 21680, cyclopentyladenosine, and IB-MECA with human neutrophils.

S S Visser1, A J Theron, G Ramafi, J A Ker, R Anderson.   

Abstract

This study was undertaken to identify the adenosine receptor (AR) subtypes which down-regulate the proinflammatory activities of human neutrophils, as well as the involvement of adenosine 3',5'-cyclic monophosphate (cAMP) and its relationship to cellular handling of Ca(2+) in mediating these effects. Neutrophils were treated with varying concentrations (0.01-1 microM) of AR agonists operative at A(1) (N(6)-cyclopentyladenosine, CPA), A(2A) (2(4-[(2-carboxyethyl)phenyl]ethylamino)-5'-N-ethylcarboxamidoadenosi ne, CGS 21680), and A(3) (N(6)-(3-iodobenzyl-5'-N-methylcarbamoyladenosine, IB-MECA) receptors, after which they were activated with the chemoattractant, N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP, 1 microM). Intracellular cAMP, superoxide, and elastase were assayed using radioimmunoassay, lucigenin-enhanced chemiluminescence (LECL), and colorimetric procedures, respectively, while changes in the concentrations of cytosolic Ca(2+) were monitored by fura-2-based spectrofluorimetry. CGS 21680, at all concentrations tested, inhibited superoxide production in a dose-related manner, while CPA and IB-MECA were effective only at the highest concentrations tested (0.5-1 microM). The release of elastase from activated neutrophils was also inhibited by all three AR agonists, but was more sensitive to CGS 21680 and IB-MECA than was superoxide production. The inhibitory effects of all 3 agonists on superoxide production and elastase release were associated with accelerated clearance of Ca(2+) from the cytosol of activated neutrophils, and were effectively neutralized by pretreatment of the cells with the highly selective A(2A)R antagonist, ZM 241385 (4-(2-[7-amino-2-(2-furyl)[1, 2,4]triazolo[2,3-a][1,3,5]triazin-5yl amino]ethyl)phenol). Increased cAMP was detected in neutrophils treated with CGS 21680 and IB-MECA (1 microM). These data support the involvement of the A(2A)R subtype in the suppression of superoxide production and degranulation by activated human neutrophils, probably by cAMP-mediated alterations in Ca(2+) handling.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10974209     DOI: 10.1016/s0006-2952(00)00414-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  18 in total

1.  P2X1 expressed on polymorphonuclear neutrophils and platelets is required for thrombosis in mice.

Authors:  Roxane Darbousset; Céline Delierneux; Soraya Mezouar; Alexandre Hego; Christelle Lecut; Isabelle Guillaumat; Markus A Riederer; Richard J Evans; Françoise Dignat-George; Laurence Panicot-Dubois; Cécile Oury; Christophe Dubois
Journal:  Blood       Date:  2014-08-22       Impact factor: 22.113

Review 2.  Taming the neutrophil: calcium clearance and influx mechanisms as novel targets for pharmacological control.

Authors:  G Tintinger; H C Steel; R Anderson
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

Review 3.  Adenosine receptors and asthma.

Authors:  Constance N Wilson; Ahmed Nadeem; Domenico Spina; Rachel Brown; Clive P Page; S Jamal Mustafa
Journal:  Handb Exp Pharmacol       Date:  2009

Review 4.  Adenosine receptors and reperfusion injury of the heart.

Authors:  John P Headrick; Robert D Lasley
Journal:  Handb Exp Pharmacol       Date:  2009

Review 5.  Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy.

Authors:  Victoria Wu; Huwate Yeerna; Nijiro Nohata; Joshua Chiou; Olivier Harismendy; Francesco Raimondi; Asuka Inoue; Robert B Russell; Pablo Tamayo; J Silvio Gutkind
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

Review 6.  Regulation of neutrophil function by adenosine.

Authors:  Kathryn E Barletta; Klaus Ley; Borna Mehrad
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04       Impact factor: 8.311

7.  Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor.

Authors:  Adam T Waickman; Angela Alme; Liana Senaldi; Paul E Zarek; Maureen Horton; Jonathan D Powell
Journal:  Cancer Immunol Immunother       Date:  2011-11-25       Impact factor: 6.968

8.  Activation of the A(3) adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils.

Authors:  Dharini van der Hoeven; Tina C Wan; John A Auchampach
Journal:  Mol Pharmacol       Date:  2008-06-26       Impact factor: 4.436

9.  A2A adenosine receptor deficiency leads to impaired tracheal relaxation via NADPH oxidase pathway in allergic mice.

Authors:  A Nadeem; D S Ponnoth; H R Ansari; T P Batchelor; R D Dey; C Ledent; S J Mustafa
Journal:  J Pharmacol Exp Ther       Date:  2009-04-24       Impact factor: 4.030

10.  Impact of anti-inflammatory agents on the gene expression profile of stimulated human neutrophils: unraveling endogenous resolution pathways.

Authors:  Mireille St-Onge; Aline Dumas; Annick Michaud; Cynthia Laflamme; Andrée-Anne Dussault; Marc Pouliot
Journal:  PLoS One       Date:  2009-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.